Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

156.19B

Market cap156.19B

Price-Earnings ratio

17.01

Price-Earnings ratio17.01

Dividend yield

2.55%

Dividend yield2.55%

Average volume

8.74M

Average volume8.74M

High today

$127.26

High today$127.26

Low today

$123.92

Low today$123.92

Open price

$125.13

Open price$125.13

Volume

4.08M

Volume4.08M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$104.46

52 Week low$104.46

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $125.80, giving the company a market capitalization of 156.19B. It carries a P/E multiple of 17.01 and pays a dividend yield of 2.55%.

During the trading session on 2026-06-24, Gilead Sciences(GILD) shares reached a daily high of $127.26 and a low of $123.92. At a current price of $125.80, the stock is +1.5% higher than the low and still -1.2% under the high.

Trading activity shows a volume of 4.08M, compared to an average daily volume of 8.74M.

The stock's 52-week range extends from a low of $104.46 to a high of $157.29.

GILD News

TipRanks 1d

Gilead announces EC grants marketing authorization for Trodelvy

Gilead (GILD) Sciences announced that the European Commission has granted marketing authorization for Trodelvy as monotherapy for the treatment of adult patient...

Investing.com 1d

Gilead’s Trodelvy wins EU approval for first-line breast cancer - Investing.com

...

Simply Wall St 2d

Gilead Sciences Stock Could Be 3.6% Undervalued After FDA Filing And Phase 3 HIV Data

Gilead Sciences (GILD) is back in focus after the FDA accepted its supplemental filing for a once-weekly oral Yeztugo tablet for HIV prevention, alongside posit...

Analyst ratings

80%

of 30 ratings

Buy

80%

Hold

20%

Sell

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.